Negotiating the prices of drugs with multiple indications presents important challenges that impact a range of stakeholders and can result in delayed patient access to potential life-saving treatments. A broad range of stakeholders was recently assembled by the UK Office of Health Economics to work toward consensus on the challenges and solutions which promote better patient access and sustainable health care and innovation. The expert panel considered that differentiating payment based on value at the indication-level represents an important part of the solution for multi-indication therapies, for which implementation must recognise divergent country health systems and experience. Considering this conclusion the present paper represents a multi-step project developed by an Italian Board of experts with the primary aim of driving a deeper understanding of the critical issues and solutions relating to access to multi-indication therapies in Italy. By starting form evidence on the positive impact of value-based differential prices on innovation and access to innovative medicines, the experts discussed and defined the specific features of payment models that could be implemented in the Italian context.
PRICING FOR MULTI INDICATION MEDICINES: A DISCUSSION WITH ITALIAN EXPERTS / Pani, L.; Cicchetti, A.; De Luca, A.; Mennini, F.S.; Mini, E.; Nocentini, G.; Racagni, G.; Jommi, C.. - In: PHARMADVANCES. - STAMPA. - 4:(2022), pp. 163-170. [10.36118/pharmadvances.2022.28]
PRICING FOR MULTI INDICATION MEDICINES: A DISCUSSION WITH ITALIAN EXPERTS
Mini, E.;
2022
Abstract
Negotiating the prices of drugs with multiple indications presents important challenges that impact a range of stakeholders and can result in delayed patient access to potential life-saving treatments. A broad range of stakeholders was recently assembled by the UK Office of Health Economics to work toward consensus on the challenges and solutions which promote better patient access and sustainable health care and innovation. The expert panel considered that differentiating payment based on value at the indication-level represents an important part of the solution for multi-indication therapies, for which implementation must recognise divergent country health systems and experience. Considering this conclusion the present paper represents a multi-step project developed by an Italian Board of experts with the primary aim of driving a deeper understanding of the critical issues and solutions relating to access to multi-indication therapies in Italy. By starting form evidence on the positive impact of value-based differential prices on innovation and access to innovative medicines, the experts discussed and defined the specific features of payment models that could be implemented in the Italian context.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.